- Pharmacists engage with patients in campaign for improved nutrition
- Report: More than a quarter of U.S. kids take at least one chronic med
- RediClinic's weight-loss program builds on current convenient care offerings
- Obesity epidemic feeds weight-loss product sales
- FDA approves Merck's Gardasil for prevention of anal cancer
SILVER SPRING, Md. — The Food and Drug Administration has approved a new weight-loss drug made by Vivus, the agency said.
The FDA announced the approval of Qsymia (phentermine and topiramate) extended-release, designed for use by overweight and obese adults alongside a reduced-calorie diet and exercise for chronic weight management. The drug's original brand name was Qnexa.
"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition."